SAN DIEGO--(BUSINESS WIRE)--MediPines, the pioneering market leader in non-invasive pulmonary gas exchange technology, and maker of AGM100, will sponsor this year’s annual UCSD John B. West Distinguished Lecture event featuring Nobel Laureate Gregg L. Semenza, MD, PhD.
The lecture, titled “Hypoxia-Inducible Factors in Physiology and Medicine,” will take place on August 7, 2023 at noon Pacific Time via livestream from UCSD.
“We’re honored to be hosting the esteemed Dr. Semenza, a pioneer and expert on studying how cells adapt to changing oxygen levels and molecular mechanisms of oxygen homeostasis,” said Dr. Jason Yuan, Professor and Director, Section of Physiology of the Division of Pulmonary, Critical Care and Sleep Medicine at UCSD. Dr. Yuan is a co-author of Ganong’s Review of Medical Physiology.
“We’re delighted to have Dr. Semenza speak on this very important topic in medicine. He is an outstanding example of a physician scientist whose work has set the bedrock for numerous clinical innovations,” said MediPines CEO, Steve Lee, who co-invented non-invasive pulmonary gas exchange monitoring technology, AGM100, with Dr. West.
Dr. Semenza, the C. Michael Armstrong Professor of Genetic Medicine at Johns Hopkins University, was awarded the Nobel Prize in Physiology or Medicine, with William G. Kaelin, Jr. and Peter J. Ratcliffe in 2019 for his groundbreaking discovery of the hypoxia-inducible factor (HIF) protein. His research on molecular mechanisms of oxygen homeostasis and oxygen sensing has generated more than 500 research articles.
After introductory notes by Zea Borok, MD (Chair of Medicine, UCSD); Jess Mandel, MD, (Chief of Pulmonary, Critical Care and Sleep Medicine, UCSD); John B. West, MD, PhD, DSc (Emeritus Professor of Medicine and Physiology at UCSD); and Steve Lee (CEO of MediPines), Dr. Semenza will deliver his lecture. After the presentation and a brief Q&A session, Dr. West will present a plaque and honorarium to Dr. Semenza.
As part of the program, there will also be a clinical presentation from a UCSD physician-scientist after the lecture.
Registration for the event can be accessed here: https://medipines.com/jbwlecture2023
Orange County, California-based MediPines is a pioneer and market leader in non-invasive pulmonary gas exchange technology. The company’s mission is to advance respiratory medicine by providing physiology-based cardiorespiratory devices that enhance clinical effectiveness and achieve superior patient outcomes. The company’s MediPines AGM100 is an industry award-winning, FDA-cleared, advanced pulmonary gas exchange technology that exclusively provides Oxygen Deficit, a non-invasive alveolar to arterial oxygen difference (AaDO2), as well as blood oxygen level (gPaO2), alveolar Carbon dioxide level (PETCO2), and other sensitive measurements of pulmonary gas exchange, relevant for respiratory (and heart) patient assessment. AGM100 is used by medical providers and clinicians to raise diagnostic accuracy, improve treatment decisions, and accelerate healthcare decision-making. The company manufactures the AGM100 in an FDA-registered MDSAP/ISO13485 certified medical manufacturing facility in California. Learn more at medipines.com.